Horm Metab Res 2003; 35(11/12): 778-785
DOI: 10.1055/s-2004-814157
Review
© Georg Thieme Verlag Stuttgart · New York

The Insulin Receptor Isoform Exon 11- (IR-A) in Cancer and Other Diseases: A Review

A.  Denley1, 2 , J.  C.  Wallace1 , L.  J.  Cosgrove2 , B.  E.  Forbes2
  • 1School of Molecular and Biomedical Sciences, The University of Adelaide, Adelaide 5005, South Australia
  • 2CSIRO Division of Health Sciences and Nutrition, Adelaide 5000, South Australia
Further Information

Publication History

Received 1 September 2003

Accepted after Revision 15 October 2003

Publication Date:
07 January 2004 (online)

Abstract

The insulin receptor plays a vital role in mediating the actions of insulin. These include metabolic and mitogenic effects. This review will focus on the role of the insulin receptor isoforms in normal development and the pathogenesis of certain cancers and type 2 diabetes. There are two insulin receptor isoforms arising from the alternative splicing of exon 11 resulting in either the exon 11+ (IR-B) isoform (including 12 amino acids encoded by exon 11) or the exon 11- (IR-A) isoform. The isoforms have different affinities for insulin, IGF-II and IGF-I with the exon 11- isoform binding both insulin and IGF-II with high affinities. Interestingly, differential expression of the insulin receptor isoforms has been demonstrated in disease. Several cancer cell types that also overexpress IGF-II preferentially express the exon 11- isoform. Activation of the exon 11- insulin receptor by IGF-II and insulin results in mitogenic effects and a potentiation of the cancer phenotype. Also hyperinsulinemia has been associated with increased risk of cancer. Differential expression of the insulin receptor isoforms has also been demonstrated in type 2 diabetes although there is some discrepancy in the literature as to which isoform is expressed.

References

  • 1 Virkamaki A, Ueki K, Kahn C R. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance.  J Clin Invest. 1999;  103 931-943
  • 2 Kahn B B, Flier J S. Obesity and insulin resistance.  J Clin Invest. 2000;  106 473-481
  • 3 Sesti G. Insulin receptor variant forms and type 2 diabetes mellitus.  Pharmacogenomics. 2000;  1 49-61
  • 4 Sesti G, Federici M, Lauro D, Sbraccia P, Lauro R. Molecular mechanism of insulin resistance in type 2 diabetes mellitus: role of the insulin receptor variant forms.  Diabetes Metab Res Rev. 2001;  17 363-373
  • 5 Zick Y. Insulin resistance: a phosphorylation-based uncoupling of insulin signaling.  Trends Cell Biol. 2001;  11 437-441
  • 6 Mauvais-Jarvis F, Kulkarni R N, Kahn C R. Knockout models are useful tools to dissect the pathophysiology and genetics of insulin resistance.  Clin Endocrinol (Oxf). 2002;  57 1-9
  • 7 Czech M P. Structural and functional homologies in the receptors for insulin and the insulin-like growth factors.  Cell. 1982;  31 8-10
  • 8 Siddle K, Urso B, Niesler C A, Cope D L, Molina L, Surinya K H, Soos M A. Specificity in ligand binding and intracellular signalling by insulin and insulin-like growth factor receptors.  Biochem Soc Trans. 2001;  29 513-525
  • 9 Adams T E, Epa V C, Garrett T P, Ward C W. Structure and function of the type 1 insulin-like growth factor receptor.  Cell Mol Life Sci. 2000;  57 1050-1093
  • 10 De Meyts P, Whittaker J. Structural biology of insulin and IGF1 receptors: implications for drug design.  Nat Rev Drug Discov. 2002;  1 769-783
  • 11 Schaefer E M, Siddle K, Ellis L. Deletion analysis of the human insulin receptor ectodomain reveals independently folded soluble subdomains and insulin binding by a monomeric alpha-subunit.  J Biol Chem. 1990;  265 13 248-13 253
  • 12 Brandt J, Andersen A S, Kristensen C. Dimeric fragment of the insulin receptor alpha-subunit binds insulin with full holoreceptor affinity.  J Biol Chem. 2001;  276 12 378-12 384
  • 13 Andersen A S, Kjeldsen T, Wiberg F C, Christensen P M, Rasmussen J S, Norris K, Moller K B, Moller N P. Changing the insulin receptor to possess insulin-like growth factor I ligand specificity.  Biochemistry. 1990;  29 7363-7366
  • 14 Kjeldsen T, Andersen A S, Wiberg F C, Rasmussen J S, Schaffer L, Balschmidt P, Moller K B, Moller N P. The ligand specificities of the insulin receptor and the insulin-like growth factor I receptor reside in different regions of a common binding site.  Proc Natl Acad Sci USA. 1991;  88 4404-4408
  • 15 Schumacher R, Mosthaf L, Schlessinger J, Brandenburg D, Ullrich A. Insulin and insulin-like growth factor-1 binding specificity is determined by distinct regions of their cognate receptors.  J Biol Chem. 1991;  266 19 288-19 295
  • 16 Wedekind F, Baer-Pontzen K, Bala-Mohan S, Choli D, Zahn H, Brandenburg D. Hormone binding site of the insulin receptor: analysis using photoaffinity-mediated avidin complexing.  Biol Chem Hoppe Seyler. 1989;  370 251-258
  • 17 Fabry M, Schaefer E, Ellis L, Kojro E, Fahrenholz F, Brandenburg D. Detection of a new hormone contact site within the insulin receptor ectodomain by the use of a novel photoreactive insulin.  J Biol Chem. 1992;  267 8950-8956
  • 18 Kurose T, Pashmforoush M, Yoshimasa Y, Carroll R, Schwartz G P, Burke G T, Katsoyannis P G, Steiner D F. Cross-linking of a B25 azidophenylalanine insulin derivative to the carboxyl-terminal region of the alpha-subunit of the insulin receptor. Identification of a new insulin-binding domain in the insulin receptor.  J Biol Chem. 1994;  269 29 190-29 197
  • 19 Williams P F, Mynarcik D C, Yu G Q, Whittaker J. Mapping of an NH2-terminal ligand binding site of the insulin receptor by alanine scanning mutagenesis.  J Biol Chem. 1995;  270 3012-3016
  • 20 Mynarcik D C, Yu G Q, Whittaker J. Alanine-scanning mutagenesis of a C-terminal ligand binding domain of the insulin receptor alpha subunit.  J Biol Chem. 1996;  271 2439-2442
  • 21 Yip C C, Jack E. Insulin receptors are bivalent as demonstrated by photoaffinity labeling.  J Biol Chem. 1992;  267 13 131-13 134
  • 22 Schaffer L. A model for insulin binding to the insulin receptor.  Eur J Biochem. 1994;  221 1127-1132
  • 23 Boni-Schnetzler M, Scott W, Waugh S M, DiBella E, Pilch P F. The insulin receptor. Structural basis for high affinity ligand binding.  J Biol Chem. 1987;  262 8395-8401
  • 24 Molina L, Marino-Buslje C, Quinn D R, Siddle K. Structural domains of the insulin receptor and IGF receptor required for dimerisation and ligand binding.  FEBS Lett. 2000;  467 226-230
  • 25 Surinya K H, Molina L, Soos M A, Brandt J, Kristensen C, Siddle K. Role of insulin receptor dimerization domains in ligand binding, cooperativity, and modulation by anti-receptor antibodies.  J Biol Chem. 2002;  277 16 718-16 725
  • 26 Frattali A L, Treadway J L, Pessin J E. Transmembrane signaling by the human insulin receptor kinase. Relationship between intramolecular beta subunit trans- and cis-autophosphorylation and substrate kinase activation.  J Biol Chem. 1992;  267 19 521-19 528
  • 27 Hubbard S R. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog.  EMBO J. 1997;  16 5572-5581
  • 28 Shepherd P R, Nave B T, Siddle K. Insulin stimulation of glycogen synthesis and glycogen synthase activity is blocked by wortmannin and rapamycin in 3T3-L1 adipocytes: evidence for the involvement of phosphoinositide 3-kinase and p70 ribosomal protein-S6 kinase.  Biochem J. 1995;  305 25-28
  • 29 Louvi A, Accili D, Efstratiadis A. Growth-promoting interaction of IGF-II with the insulin receptor during mouse embryonic development.  Dev Biol. 1997;  189 33-48
  • 30 Kitamura T, Kahn C R, Accili D. Insulin receptor knockout mice.  Annu Rev Physiol. 2003;  65 313-332
  • 31 Kondo T, Vicent D, Suzuma K, Yanagisawa M, King G L, Holzenberger M, Kahn C R. Knockout of insulin and IGF-1 receptors on vascular endothelial cells protects against retinal neovascularization.  J Clin Invest. 2003;  111 1835-1842
  • 32 Entingh A J, Taniguchi C M, Kahn C R. Bi-directional regulation of brown fat adipogenesis by the insulin receptor.  J Biol Chem. 2003;  278 33 377-33 383
  • 33 Kulkarni R N, Bruning J C, Winnay J N, Postic C, Magnuson M A, Kahn C R. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes.  Cell. 1999;  96 329-339
  • 34 Lauro D, Kido Y, Castle A L, Zarnowski M J, Hayashi H, Ebina Y, Accili D. Impaired glucose tolerance in mice with a targeted impairment of insulin action in muscle and adipose tissue.  Nat Genet. 1998;  20 294-298
  • 35 Michael M D, Kulkarni R N, Postic C, Previs S F, Shulman G I, Magnuson M A, Kahn C R. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction.  Mol Cell. 2000;  6 87-97
  • 36 Fisher S J, Kahn C R. Insulin signaling is required for insulin’s direct and indirect action on hepatic glucose production.  J Clin Invest. 2003;  111 463-468
  • 37 Ebina Y, Ellis L, Jarnagin K, Edery M, Graf L, Clauser E, Ou J H, Masiarz F, Kan Y W, Goldfine I D. et al . The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signalling.  Cell. 1985;  40 747-758
  • 38 Ullrich A, Bell J R, Chen E Y, Herrera R, Petruzzelli L M, Dull T J, Gray A, Coussens L, Liao Y C, Tsubokawa M. et al . Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes.  Nature. 1985;  313 756-761
  • 39 Seino S, Seino M, Nishi S, Bell G I. Structure of the human insulin receptor gene and characterization of its promoter.  Proc Natl Acad Sci USA. 1989;  86 114-118
  • 40 Seino S, Bell G I. Alternative splicing of human insulin receptor messenger RNA.  Biochem Biophys Res Commun. 1989;  159 312-316
  • 41 Moller D E, Yokota A, Caro J F, Flier J S. Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man.  Mol Endocrinol. 1989;  3 1263-1269
  • 42 Mosthaf L, Grako K, Dull T J, Coussens L, Ullrich A, McClain D A. Functionally distinct insulin receptors generated by tissue-specific alternative splicing.  EMBO J. 1990;  9 2409-2413
  • 43 Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, Goldfine I D, Belfiore A, Vigneri R. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells.  Mol Cell Biol. 1999;  19 3278-3288
  • 44 Kosaki A, Nelson J, Webster N J. Identification of intron and exon sequences involved in alternative splicing of insulin receptor pre-mRNA.  J Biol Chem. 1998;  273 10 331-10 337
  • 45 Savkur R S, Philips A V, Cooper T A. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy.  Nat Genet. 2001;  29 40-47
  • 46 McClain D A. Different ligand affinities of the two human insulin receptor splice variants are reflected in parallel changes in sensitivity for insulin action.  Mol Endocrinol. 1991;  5 734-739
  • 47 Yamaguchi Y, Flier J S, Yokota A, Benecke H, Backer J M, Moller D E. Functional properties of two naturally occurring isoforms of the human insulin receptor in Chinese hamster ovary cells.  Endocrinology. 1991;  129 2058-2066
  • 48 Yamaguchi Y, Flier J S, Benecke H, Ransil B J, Moller D E. Ligand-binding properties of the two isoforms of the human insulin receptor.  Endocrinology. 1993;  132 1132-1138
  • 49 Kotzke G, Schutt M, Missler U, Moller D E, Fehm H L, Klein H H. Binding of human, porcine and bovine insulin to insulin receptors from human brain, muscle and adipocytes and to expressed recombinant alternatively spliced insulin receptor isoforms.  Diabetologia. 1995;  38 757-763
  • 50 Kellerer M, Lammers R, Ermel B, Tippmer S, Vogt B, Obermaier-Kusser B, Ullrich A, Haring H U. Distinct alpha-subunit structures of human insulin receptor A and B variants determine differences in tyrosine kinase activities.  Biochemistry. 1992;  31 4588-4596
  • 51 Kosaki A, Pillay T S, Xu L, Webster N J. The B isoform of the insulin receptor signals more efficiently than the A isoform in HepG2 cells.  J Biol Chem. 1995;  270 20 816-20 823
  • 52 Vogt B, Carrascosa J M, Ermel B, Ullrich A, Haring H U. The two isotypes of the human insulin receptor (HIR-A and HIR-B) follow different internalization kinetics.  Biochem Biophys Res Commun. 1991;  177 1013-1018
  • 53 Whittaker J, Sorensen H, Gadsboll V L, Hinrichsen J. Comparison of the functional insulin binding epitopes of the A and B isoforms of the insulin receptor.  J Biol Chem. 2002;  277 47 380-47 384
  • 54 Leibiger B, Leibiger I B, Moede T, Kemper S, Kulkarni R N, Kahn C R, de Vargas L M, Berggren P O. Selective insulin signaling through A and B insulin receptors regulates transcription of insulin and glucokinase genes in pancreatic beta cells.  Mol Cell. 2001;  7 559-570
  • 55 Sciacca L, Prisco M, Wu A, Belfiore A, Vigneri R, Baserga R. Signaling differences from the A and B isoforms of the insulin receptor (IR) in 32D cells in the presence or absence of IR substrate-1.  Endocrinology. 2003;  144 2650-2658
  • 56 Kosaki A, Webster N J. Effect of dexamethasone on the alternative splicing of the insulin receptor mRNA and insulin action in HepG2 hepatoma cells.  J Biol Chem. 1993;  268 21 990-21 996
  • 57 Sell S M, Reese D, Ossowski V M. Insulin-inducible changes in insulin receptor mRNA splice variants.  J Biol Chem. 1994;  269 30 769-30 772
  • 58 Norgren S, Li L S, Luthman H. Regulation of human insulin receptor RNA splicing in HepG2 cells: effects of glucocorticoid and low glucose concentration.  Biochem Biophys Res Commun. 1994;  199 277-284
  • 59 Hribal M L, Perego L, Lovari S, Andreozzi F, Menghini R, Perego C, Finzi G, Usellini L, Placidi C, Capella C, Guzzi V, Lauro D, Bertuzzi F, Davalli A, Pozza G, Pontiroli A, Federici M, Lauro R, Brunetti A, Folli F, Sesti G. Chronic hyperglycemia impairs insulin secretion by affecting insulin receptor expression, splicing, and signaling in RIN beta cell line and human islets of Langerhans.  FASEB J. 2003;  17 1340-1342
  • 60 Lou Y, Zee R Y, Li M, Morris B J. No difference in the proportion of insulin receptor exon 11 +/- isoform mRNA in the liver of rats after development of hypertension.  Clin Exp Pharmacol Physiol. 1996;  23 602-604
  • 61 Anderson C M, Henry R R, Knudson P E, Olefsky J M, Webster N J. Relative expression of insulin receptor isoforms does not differ in lean, obese, and noninsulin-dependent diabetes mellitus subjects.  J Clin Endocrinol Metab. 1993;  76 1380-1382
  • 62 Vidal H, Auboeuf D, Beylot M, Riou J P. Regulation of insulin receptor mRNA splicing in rat tissues. Effect of fasting, aging, and diabetes.  Diabetes. 1995;  44 1196-1201
  • 63 Wiersma M M, Auboeuf D, Nieuwenhuizen-Bakker I M, Radder J K, Riou J P, Vidal H. Insulin receptor mRNA splicing and altered metabolic control in aged and mildly insulin-deficient rats.  Am J Physiol. 1997;  272 E607-615
  • 64 van der Vorm E R, Maassen J A. Alternative splicing of the insulin receptor isoforms is altered in patients with leprechaunism.  Horm Metab Res. 1994;  26 599-601
  • 65 Sciacca L, Costantino A, Pandini G, Mineo R, Frasca F, Scalia P, Sbraccia P, Goldfine I D, Vigneri R, Belfiore A. Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism.  Oncogene. 1999;  18 2471-2479
  • 66 Kalli K R, Falowo O I, Bale L K, Zschunke M A, Roche P C, Conover C A. Functional insulin receptors on human epithelial ovarian carcinoma cells: implications for IGF-II mitogenic signaling.  Endocrinology. 2002;  143 3259-3267
  • 67 Vella V, Pandini G, Sciacca L, Mineo R, Vigneri R, Pezzino V, Belfiore A. A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer.  J Clin Endocrinol Metab. 2002;  87 245-254
  • 68 Sciacca L, Mineo R, Pandini G, Murabito A, Vigneri R, Belfiore A. In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A.  Oncogene. 2002;  21 8240-8250
  • 69 von Horn H, Tally M, Hall K, Eriksson T, Ekstrom T J, Gray S G. Expression levels of insulin-like growth factor binding proteins and insulin receptor isoforms in hepatoblastomas.  Cancer Lett. 2001;  162 253-260
  • 70 LeRoith D, Roberts C T Jr. The insulin-like growth factor system and cancer.  Cancer Lett. 2003;  195 127-137
  • 71 Morrione A, Valentinis B, Xu S Q, Yumet G, Louvi A, Efstratiadis A, Baserga R. Insulin-like growth factor II stimulates cell proliferation through the insulin receptor.  Proc Natl Acad Sci USA. 1997;  94 3777-3782
  • 72 Gicquel C, Bertagna X, Schneid H, Francillard-Leblond M, Luton J P, Girard F, Le Bouc Y. Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors.  J Clin Endocrinol Metab. 1994;  78 1444-1453
  • 73 Renehan A G, Jones J, Potten C S, Shalet S M, O’Dwyer S T. Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer.  Br J Cancer. 2000;  83 1344-1350
  • 74 Quinn K A, Treston A M, Unsworth E J, Miller M J, Vos M, Grimley C, Battey J, Mulshine J L, Cuttitta F. Insulin-like growth factor expression in human cancer cell lines.  J Biol Chem. 1996;  271 11 477-11 483
  • 75 Cui H, Cruz-Correa M, Giardiello F M, Hutcheon D F, Kafonek D R, Brandenburg S, Wu Y, He X, Powe N R, Feinberg A P. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk.  Science. 2003;  299 1753-1755
  • 76 Okamoto K, Morison I M, Taniguchi T, Reeve A E. Epigenetic changes at the insulin-like growth factor II/ H19 locus in developing kidney is an early event in Wilms tumorigenesis.  Proc Natl Acad Sci USA. 1997;  94 5367-5371
  • 77 Cullen K J, Lippman M E, Chow D, Hill S, Rosen N, Zwiebel J A. Insulin-like growth factor-II overexpression in MCF-7 cells induces phenotypic changes associated with malignant progression.  Mol Endocrinol. 1992;  6 91-100
  • 78 Devi G R, De Souza A T, Byrd J C, Jirtle R L, MacDonald R G. Altered ligand binding by insulin-like growth factor II/mannose 6-phosphate receptors bearing missense mutations in human cancers.  Cancer Res. 1999;  59 4314-4319
  • 79 Byrd J C, Devi G R, de Souza A T, Jirtle R L, MacDonald R G. Disruption of ligand binding to the insulin-like growth factor II/mannose 6-phosphate receptor by cancer-associated missense mutations.  J Biol Chem. 1999;  274 24 408-24 416
  • 80 Osipo C, Dorman S, Frankfater A. Loss of insulin-like growth factor II receptor expression promotes growth in cancer by increasing intracellular signaling from both IGF-I and insulin receptors.  Exp Cell Res. 2001;  264 388-396
  • 81 Souza R F, Wang S, Thakar M, Smolinski K N, Yin J, Zou T T, Kong D, Abraham J M, Toretsky J A, Meltzer S J. Expression of the wild-type insulin-like growth factor II receptor gene suppresses growth and causes death in colorectal carcinoma cells.  Oncogene. 1999;  18 4063-4068
  • 82 Pandini G, Medico E, Conte E, Sciacca L, Vigneri R, Belfiore A. Differential gene expression induced by insulin and IGF-ii through the insulin receptor isoform A.  J Biol Chem. 2003;  278 42 178-42 189
  • 83 Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence.  J Nutr. 2001;  131 3109S-31020S
  • 84 Meyerhardt J A, Catalano P J, Haller D G, Mayer R J, Macdonald J S, Benson A B, 3rd , Fuchs C S. Impact of diabetes mellitus on outcomes in patients with colon cancer.  J Clin Oncol. 2003;  21 433-440
  • 85 Huang Z, Bodkin N L, Ortmeyer H K, Hansen B C, Shuldiner A R. Hyperinsulinemia is associated with altered insulin receptor mRNA splicing in muscle of the spontaneously obese diabetic rhesus monkey.  J Clin Invest. 1994;  94 1289-1296
  • 86 Paz K, Hemi R, LeRoith D, Karasik A, Elhanany E, Kanety H, Zick Y. A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation.  J Biol Chem. 1997;  272 29 911-29 918
  • 87 Kellerer M, Sesti G, Seffer E, Obermaier-Kusser B, Pongratz D E, Mosthaf L, Haring H U. Altered pattern of insulin receptor isotypes in skeletal muscle membranes of type 2 (non-insulin-dependent) diabetic subjects.  Diabetologia. 1993;  36 628-632
  • 88 Sesti G, D’Alfonso R, Vargas P unti, Frittitta L, Trischitta V, Liu Y Y, Borboni P, Longhi R, Montemurro A, Lauro R. Peptide-based radioimmunoassay for the two isoforms of the human insulin receptor.  Diabetologia. 1995;  38 445-453
  • 89 Norgren S, Zierath J, Galuska D, Wallberg-Henriksson H, Luthman H. Differences in the ratio of RNA encoding two isoforms of the insulin receptor between control and NIDDM patients. The RNA variant without Exon 11 predominates in both groups.  Diabetes. 1993;  42 675-681
  • 90 Benecke H, Flier J S, Moller D E. Alternatively spliced variants of the insulin receptor protein. Expression in normal and diabetic human tissues.  J Clin Invest. 1992;  89 2066-2070
  • 91 Norgren S, Zierath J, Wedell A, Wallberg-Henriksson H, Luthman H. Regulation of human insulin receptor RNA splicing in vivo.  Proc Natl Acad Sci USA. 1994;  91 1465-1469
  • 92 Soos M A, Field C E, Siddle K. Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity.  Biochem J. 1993;  290 419-426
  • 93 Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R, Belfiore A. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved.  J Biol Chem. 2002;  277 39 684-39 695
  • 94 Belfiore A, Pandini G, Vella V, Squatrito S, Vigneri R. Insulin/IGF-I hybrid receptors play a major role in IGF-I signaling in thyroid cancer.  Biochimie. 1999;  81 403-407
  • 95 Pandini G, Vigneri R, Costantino A, Frasca F, Ippolito A, Fujita-Yamaguchi Y, Siddle K, Goldfine I D, Belfiore A. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling.  Clin Cancer Res. 1999;  5 1935-1944
  • 96 Garrouste F L, Remacle-Bonnet M M, Lehmann M M, Marvaldi J L, Pommier G J. Up-regulation of insulin/insulin-like growth factor-I hybrid receptors during differentiation of HT29-D4 human colonic carcinoma cells.  Endocrinology. 1997;  138 2021-2032
  • 97 Federici M, Zucaro L, Porzio O, Massoud R, Borboni P, Lauro D, Sesti G. Increased expression of insulin/insulin-like growth factor-I hybrid receptors in skeletal muscle of noninsulin-dependent diabetes mellitus subjects.  J Clin Invest. 1996;  98 2887-2893
  • 98 Federici M, Porzio O, Zucaro L, Giovannone B, Borboni P, Marini M A, Lauro D, Sesti G. Increased abundance of insulin/IGF-I hybrid receptors in adipose tissue from NIDDM patients.  Mol Cell Endocrinol. 1997;  135 41-47
  • 99 Ullrich A, Gray A, Tam A W, Yang-Feng T, Tsubokawa M, Collins C, Henzel W, Le Bon T, Kathuria S, Chen E. et al . Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity.  EM BO J. 1986;  5 2503-2512

A. Denley

School of Molecular and Biomedical Sciences · The University of Adelaide

Adelaide 5005 · South Australia

Phone: +61(8)8303-5581

Fax: +61(8)8303-4348

Email: adam.denley@adelaide.edu.au

    >